Pulse Biosciences (Nasdaq:PLSE) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

PLSE 주식 개요

펄스 바이오사이언스는 새로운 바이오 전기 의약품 회사로 운영되고 있습니다.

PLSE 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

지난 5년 동안 수입이 매년 0.2% 증가했습니다.

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

최근 3개월간 주가 변동폭 심해

지난 1년 동안 주주가 희석되었습니다.

Pulse Biosciences, Inc. 경쟁사

ZimVie

NasdaqGS:ZIMV

US$434.5m

Integra LifeSciences Holdings

NasdaqGS:IART

US$1.4b

Artivion

NYSE:AORT

US$1.1b

NovoCure

NasdaqGS:NVCR

US$1.7b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Pulse Biosciences
과거 주가
현재 주가	US$17.21
52주 최고치	US$22.69
52주 최저치	US$3.78
베타	1.75
11개월 변경	-7.70%
3개월 변경 사항	58.86%
1년 변경 사항	326.92%
33년 변화	-20.86%
5년 변화	18.17%
IPO 이후 변화	312.59%

최근 뉴스 및 업데이트

Recent updates

What Percentage Of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Do Insiders Own?

Jan 20

Pulse Biosciences' CellFX System U.S. application moves forward for general dermatology indication

Jan 12

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Dec 16

주주 수익률

	PLSE	US Medical Equipment	US 마켓
7D	-3.7%	-0.8%	0.7%
1Y	326.9%	21.2%	32.3%

수익률 대 산업: PLSE 지난 1년 동안 9.8 %를 반환한 US Medical Equipment 산업을 초과했습니다.

수익률 대 시장: PLSE 지난 1년 동안 25.4 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is PLSE's price volatile compared to industry and market?
PLSE volatility
PLSE Average Weekly Movement	15.3%
Medical Equipment Industry Average Movement	8.8%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

안정적인 주가: PLSE 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: PLSE 의 주간 변동성( 18% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2019	56	Burke Barrett	www.pulsebiosciences.com

펄스 바이오사이언스는 새로운 바이오 전기 의학 회사로 운영되고 있습니다. 이 회사는 나노 펄스 자극 기술을 사용하여 다양한 의학적 상태를 치료하기 위해 인접한 비세포 조직은 살리면서 열을 가하지 않는 표적 세포에 나노초 길이의 전기 에너지 펄스를 전달하는 조정 가능한 소프트웨어 지원 콘솔 기반 플랫폼인 CellFX 시스템을 제공합니다. 이 회사는 이전에 일렉트로블레이트(Electroblate, Inc.)로 알려졌으나 2015년 12월에 펄스 바이오사이언스로 사명을 변경했습니다.

Pulse Biosciences, Inc. 기본 사항 요약

Pulse Biosciences 의 수익과 매출은 시가총액과 어떻게 비교하나요?
PLSE 기본 통계
시가총액	US$1.05b
수익(TTM)	-US$44.02m
수익(TTM)	n/a

0.0x

P/S 비율

-24.0x

P/E 비율

PLSE 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
PLSE 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$44.02m
수익	-US$44.02m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.72
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

PLSE 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

PLSE 주식 개요

보상

위험 분석

Pulse Biosciences, Inc. 경쟁사

NasdaqGS:ZIMV

US$434.5m

NasdaqGS:IART

US$1.4b

NYSE:AORT

US$1.1b

NasdaqGS:NVCR

US$1.7b

가격 내역 및 성능

최근 뉴스 및 업데이트

Pulse Biosciences, Inc. announced delayed 10-Q filing

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Pulse Biosciences, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Pulse Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Recent updates

Pulse Biosciences, Inc. announced delayed 10-Q filing

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Pulse Biosciences, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Pulse Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell Small Cap Comp Value Index

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought US$86k worth of stock

Pulse Biosciences Stock: Signs Of Life Following Q1 Update

Pulse Biosciences, Inc Announces CEO Changes

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

New major risk - Financial position

Pulse Biosciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Pulse Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter

Executive Chairman exercised options to buy US$382k worth of stock.

Executive Chairman recently bought US$1.1m worth of stock

Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode

Chief Strategy Officer recently bought US$105k worth of stock

Executive Chairman exercised options to buy US$68k worth of stock.

Pulse Biosciences, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

New major risk - Revenue and earnings growth

Pulse Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Executive Chairman exercised options to buy US$881k worth of stock.

Executive Chairman exercised options to buy US$36m worth of stock.

Independent Director exercised options to buy US$543k worth of stock.

Pulse Biosciences, Inc. Appoints f Gansevoort 'Gan' Dunnington, M.D. as Its Chief Medical Officer

Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?

Pulse Biosciences, Inc. Announces Resignation of Sandra Gardiner as Chief Financial Officer

Pulse Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Chief Strategy Officer & Director recently bought US$70k worth of stock

Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions

Pulse Biosciences, Inc. Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia

Pulse Biosciences, Inc. Announces Executive Changes

Pulse Biosciences appoints Kevin Danahy as CEO; Darrin Uecker to serve as CTO

Consensus revenue estimates fall by 31%

Pulse Biosciences, Inc. Receives FDA 510(K) Clearance of Expanded Energy Settings for Use with the CellFX System

Pulse Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 2000 Dynamic Index

Pulse Biosciences, Inc. has completed a Composite Units Offering in the amount of $15 million.

Consensus forecasts updated

Price target decreased to US$11.17

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc

Consensus forecasts updated

Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky

Pulse Biosciences, Inc., Annual General Meeting, May 19, 2022

Pulse Biosciences, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Pulse Biosciences, Inc

Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer

Pulse Biosciences, Inc Provides an Update on Recent FDA 510(k) Submission

Price target decreased to US$35.33